EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors

Lisa Reichert, Aro Delparente, Ida R Hipfinger, Lukas Reininger, Ana Pinto Castro, Daniel J Hubin, Roger Schibli, Amy E Fraley iD, Linjing Mu

ChemMedChem · 2026-07-29 · 21 (14)

DOI: 10.1002/cmdc.70399 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-07-27. Written by Lisa Reichert and 8 co-authors. Institution: Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland. Major MEDLINE topics: Enzyme Inhibitors, Pyrazolones, Pyrazoles. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Swiss National Fundation, Novartis Stiftung für Medizinisch-Biologische Forschung.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

In a recent study, the oxadiazin‐5‐one‐based compound CJ1‐34 was identified as a partial ATP synthase inhibitor, which was found to bind the F 1 region of the ATP synthase. These findings were used as a starting point for the design and synthesis of smaller heterocycles, such as pyrazolidine‐3‐ones and pyrazol‐3‐ones, as novel structural scaffolds for potential ATP synthase inhibitors. Among the newly synthesized compounds, pyrazolidin‐3‐one derivatives 9a and 10a outperformed the lead compound CJ1‐34 in vitro by inhibiting ATP hydrolytic activity and decreasing ATP levels in HT‐22 cells. Subsequent dose‐dependent studies identified compound 9a as the most promising ATP synthase inhibitor. Molecular docking revealed similar binding modes for all compounds in the F1‐binding site and the calculated docking scores aligned with the measured IC 50 values of the tested compounds. This study identified pyrazolidine‐3‐ones as promising structural scaffolds for ATP synthase inhibition, opening avenues for further biomedical applications in central nervous system diseases such as Alzheimer's and Parkinson's.

Subjects

MeSH terms (MEDLINE)

Enzyme InhibitorsPyrazolonesPyrazolesStructure-Activity RelationshipMolecular Docking SimulationHumansDose-Response Relationship, DrugMolecular StructureAdenosine TriphosphateBinding SitesCell LineAnimals

Author keywords

ATP synthasein vitro evaluationmolecular dockingpyrazolidin‐3‐onespyrazol‐3‐ones

Substances

Enzyme InhibitorsPyrazolonesAdenosine TriphosphatePyrazolespyrazolidine

Authors and institutions

  • Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Zurich, Switzerland.

ORCID profiles: Amy E Fraley

Funding

  • Swiss National Fundation
  • Novartis Stiftung für Medizinisch-Biologische Forschung

Cite

APA

Reichert, L., Delparente, A., Hipfinger, I. R., Reininger, L., Castro, A. P., Hubin, D. J., Schibli, R., Fraley, A. E., & Mu, L. (2026). Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors. ChemMedChem, 21(14). https://doi.org/10.1002/cmdc.70399

Vancouver

Reichert L, Delparente A, Hipfinger IR, Reininger L, Castro AP, Hubin DJ, et al. Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors. ChemMedChem. 2026;21(14). doi:10.1002/cmdc.70399

BibTeX
@article{Reichert2026,
  author = {Reichert, Lisa and Delparente, Aro and Hipfinger, Ida R and Reininger, Lukas and Castro, Ana Pinto and Hubin, Daniel J and Schibli, Roger and Fraley, Amy E and Mu, Linjing},
  title = {Identification of Pyrazolidine‐3‐One Derivatives as a Novel Structural Scaffold for ATP Synthase Inhibitors},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {14},
  doi = {10.1002/cmdc.70399}
}
Start for free →